FTC Signs Off On Grifols-Talecris Deal Divestitures

Law360, New York (June 1, 2011, 1:32 PM EDT) -- The Federal Trade Commission signed off Wednesday on Grifols SA’s antitrust-related divestitures of two plasma collection centers and a blood fractionation facility as part of its $3.4 billion purchase of rival medical researcher Talecris Biotherapeutics Holdings Corp.

The commission voted 4-0 to approve the settlement; Commissioner William E. Kovacic recused himself and Commissioner Julie Brill issued a concurring statement calling the approval "a close call" as to whether it does enough to remedy competition concerns.

The vote clears the way for the merger, announced in June...
To view the full article, register now.